Abstract 5664: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release
Ramesh Baliga(IGM Biosciences (United States)), Bruce A. Keyt, Stephen F. Carroll(IGM Biosciences (United States)), Daniel S. Chen(Synthetic Genomics (United States)), Yuan Cao(IGM Biosciences (United States)), Marigold Manlusoc(IGM Biosciences (United States)), Sachi Rahman(IGM Biosciences (United States)), Dean Ng(IGM Biosciences (United States)), Keyu Li(Sichuan University), Bing Shan(Chinese Academy of Sciences), Madeline Tran(IGM Biosciences (United States)), Marvin S. Peterson(IGM Biosciences (United States)), Hai Lu(IGM Biosciences (United States)), Paul R. Hinton(IGM Biosciences (United States)), Avneesh K. Saini(IGM Biosciences (United States)), Chitra Saraiya(IGM Biosciences (United States))
Cited by 3
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
|Proceedings of the National Academy of Sciences|1986|518